Further study details as provided by The HIV Netherlands Australia Thailand Research Collaboration:

Primary Outcome Measures:

1. To collect clinical and immunologic data of children treated with HAART 2. To collect clinical outcome data on children with HIV infection 3. To provide the best possible care to children with HIV infection [ Time Frame: every 3 months ] [ Designated as safety issue: No ]

This is a long term cohort study that was started in 2002. Currently, there are 120 children enrolled in the study and are receiving HIV care according to standard practice set by the Thai Ministry of Public Health. HIV-infected parents also receive care at the same clinic.

Eligibility

Ages Eligible for Study:

up to 20 Years (Child, Adult)

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Sampling Method:

Non-Probability Sample

Study Population

HIV-infected infants, children and adolescents (range age 1 day - 20 years old) who have participated in HIV-NAT trials

Criteria

Inclusion Criteria:

Children who are part of the ATC program at Chulalongkorn hospital and at HIV-NAT, The Thai Red Cross AIDS research center

Children who fulfil criteria to start HAART according to the ATC program

Children who are switched to second regimen or salvage therapy

Children who are on any antiretroviral regimens, including post trial children from other HIV-NAT study (both at HIV-NAT and Khon Kaen University sites)

Children with HIV infection who are not on antiretroviral therapy

Caretakers understand the purpose of data and plasma samples collection, and have signed the consent form

Exclusion Criteria:

Patients and caretakers may choose to stop HAART at anytime during the study. If they agree, we would continue to follow them in this study.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00476606